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Background: Clinical interpretation of health related quality of life (HRQOL) scores is challenging. The purpose of
this analysis was to interpret score changes and identify minimal clinically important differences (MCID) on the
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30)
before (T1) and during (T2) cancer treatment.
Methods: Patients (N = 627) in stem cell transplant (SCT) and medical (MED) or radiation (RAD) oncology at two
comprehensive cancer centers, enrolled in the Electronic Self-Report Assessment-Cancer study and completed the
QLQ-C30 at T1 and T2. Perceived changes in five QOL domains, physical (PF), emotional (EF), social (SF), cognitive
functioning (CF) and global quality of life (QOL), were reported using the Subject Significance Questionnaire (SSQ)
at T2. Anchored on SSQ ratings indicating “improvement”, “the same”, or “deterioration”, means and effect sizes
were calculated for QLQ-C30 score changes. MCID was calculated as the mean difference in QLQ-C30 score
changes reflecting one category change on SSQ rating, using a two-piece linear regression model.
Results: A majority of SCT patients (54%) perceived deteriorating global HRQOL versus improvement (17%), while
approximately equal proportions of MED/RAD patients perceived improvement (25%) and deterioration (26%).
Global QOL decreased 14.2 (SCT) and 2.0 (MED/RAD) units, respectively, among patients reporting “the same” in the
SSQ. The MCID ranged 5.7-11.4 (SCT) and 7.2-11.8 (MED/RAD) units among patients reporting deteriorated HRQOL;
ranged 2.7-3.4 units among MED/RAD patients reporting improvement. Excepting for the global QOL (MCID =6.9),
no meaningful MCID was identified among SCT patients reporting improvement.
Conclusions: Cancer treatment has greater impact on HRQOL among SCT patients than MED/RAD patients. The
MCID for QLQ-C30 score change differed across domains, and differed for perceived improvement and
deterioration, suggesting different standards for self-evaluating changes in HRQOL during cancer treatment.
Specifically, clinical attention can be focused on patients who report at least a 6 point decrease, and for patients
who report at least a 3 point increase on QLQ-C30 domains.
Trial registration: The trial was registered with ClinicalTrials.gov: NCT00852852
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Health-related quality of life (HRQOL) is an important pa-
tient outcome measure following cancer treatment in ran-
domized trials. HRQOL was shown to be an independent
prognostic factor for response to treatment, progression-
free survival, and survival [1,2]. Significance of differences
(or changes) in HRQOL are often interpreted with stat-
istical hypothesis testing using p-values [3]. However, a
statistically significant difference is not synonymous
with clinical meaningfulness. Clinical investigators are
challenged to interpret important changes in HRQOL
over time and to determine a minimal clinically important
difference (MCID). Once established, a MCID is a useful
benchmark for clinical researchers to assess effectiveness of
an intervention and determine sample sizes for future clin-
ical trials. Understanding the MCID may help clinicians ad-
dress HRQOL related issues during cancer treatment.
The European Organization for the Research and Treat-
ment of Cancer (EORTC) Quality of Life Questionnaire
Core 30 (QLQ-C30) [4] is a commonly used instrument
for measuring HRQOL among cancer patients. Osoba et al.
evaluated 375 patients with metastatic small cell lung
cancer or breast cancer, and observed a mean change of
5–10, 10–20, >20 units for small, moderate, large changes,
respectively, in QLQ-C30 scores [5]. In a review of 14
cross-sectional studies, King et al. recommended that a
change of 5 and 15 units was a relatively small and large
difference, respectively [6]. On the contrary, Grulke and
colleagues evaluated trends in HRQOL scores before
and after hematopoietic stem cell transplant (SCT) from
33 studies that involved 2,800 patients in England and
Germany, and concluded that only a difference exceed-
ing 15 units was clinically significant [7]. Additionally,
in a meta-analysis of 152 cross-sectional studies (15%
were conducted in the US/Canada regions), Cocks et al.
recommended a range of 9 to 19 points as the medium
difference [8]. Most of these studies analyzed data among
European patients, and focused on patients with specific
cancer types. To our knowledge, our analysis is the first to
interpret and to identify MCIDs for the QLQ-C30 score
changes focusing on American patients with cancer.
There are few analyses assessing potential differ-
ences in MCID between improvement and deterior-
ation. Ringash et al [9] and Cella et al [10] analyzed
the Functional Assessment of Cancer Therapy (FACT)
and reported a larger magnitude in MCID for deteri-
oration than for improvement. This is in contrast to a
study using QLQ-C30 among patients treated for brain
cancer, in which Maringwa and colleagues suggested no
clear indications that the MCID differed between im-
provement and deterioration [11]. Kvam et al. reported
a MCID of 8 and 12 units in QLQ-C30 for improved
and deteriorated HRQOL among patients with multiple
myeloma [12]. Both of the two studies focused on specificpatient population. Using a unique approach of assem-
bling expert opinions, Cocks et al. reported smaller
estimates for improvement than for declines in a meta-
analysis of 118 published longitudinal studies [13]. It is
not yet established whether the different magnitudes
of MCID should be used in QLQ-C30 as clinically
meaningful benchmark for improvement and deterioration.
One well-accepted definition for MCID is “the smallest
difference in score in the domain of interest which pa-
tients perceived as beneficial and which would mandate,
in the absence of troublesome side effects and excessive
cost, a change in the patient’s management” [14], p. 408.
Two approaches are commonly used to assess MCID.
The distribution-based approach utilizes the statistical fea-
tures, such as fractions of the standard deviation (SD).
The anchor-based approach is preferred because it uses
patient-derived ratings rather than statistical significance
[5]. In the current analysis, we used an anchored-based
approach based on the methodology introduced by Osoba
et al. in which patients were asked to rate their perceived
change in HRQOL over time using the Subject Signifi-
cance Questionnaire (SSQ) [15].
The objectives of this analysis were (a) to report and
interpret HRQOL change measured by QLQ-C30, and
(b) to determine the MCID for the QLQ-C30 change
scores over time before and during cancer therapy among
American patients with various types of cancer.
Methods
Study sample
A total of 765 adult, ambulatory patients with any type
of cancer, who started a new medical, radiation or stem-
cell transplantation treatment at one of two comprehen-
sive cancer centers (Seattle Cancer Care Alliance or the
University Of Washington Medical Center) were enrolled
into the Electronic Self-Report Assessment for Cancer
(ESRA-C) intervention trial (NCT00852852). The study
was approved by the Institutional Review Board of the
Fred Hutchinson Cancer Research Center/University of
Washington Cancer Consortium. The primary outcome
was reported elsewhere [16].
Using touch-screen, notebook computers, patients com-
pleted e-versions of the QLQ-C30 pre-treatment (T1) and
during treatment (T2). Most of the SCT patients answered
the T2 assessment at the first, post-hospital discharge
clinic visit. At T2, patients reported perceived changes
in quality of life by completing a seven-point response
category SSQ. Eighty-six percent (n = 660) completed the
T2 assessment. Additional details of the full sample and
study procedures have been reported previously [16].
Analytic variables
Patients reported socidemographic characteristics at enroll-
ment. Information on cancer type and incident or recurrent
Hong et al. BMC Cancer 2013, 13:165 Page 3 of 8
http://www.biomedcentral.com/1471-2407/13/165diagnosis was abstracted from medical records. The QLQ-
C30 [4] is a cancer-specific quality of life instrument with
five functional subscale scales- physical (PF), role (RF),
emotional (EF), social (SF) and cognitive (CF) functioning,
plus global QOL. The QLQ-C30 summary scores for each
domain were transformed to range from 0 to 100 according
to published methods for version 3 [17]. Higher functional
and global QOL scores correspond to a higher level of
functioning. For the current study, alpha coefficients for
the subscales ranged from 0.66 (CF) to 0.87 (global QOL)
at T1 and 0.70 (CF) to 0.89 (global QOL) at T2.
The five SSQ items correspond with the QLQ-C30 do-
mains of PF, EF, SF, CF and global QOL. The SSQ queries
patients about their perceived level of change in each of
the domains using a seven-point scale ranging from (1)
very much worse, (2) moderately worse, (3) a little worse,
(4) about the same, (5) a little better, (6) moderately better,
to (7) very much better. The SSQ instrument has been
used as a calibration instrument to assess the magnitude









Race, minority or multiple 13
Some college or college graduate 146
Married/Partnered 138
Low annual household income (<=$35,000) 44
Study Group (Intervention)* 92












Days between T1 and T2, days
Median, range 42
*In the intervention group, Patient-reported quality-of-life issues were automatically
an on-treatment visit; in the control group, no summary was provided. Details on smeaningful to patients as measured by validated instru-
ments such as the QLQ-C30 [5,15,18]. We analyzed the
PF, EF, SF CF, and global QOL domains in comparison to
the corresponding SSQ items.
Statistical analysis
Baseline demographic and clinical characteristics were
summarized using descriptive statistics among SCT and
MED/RAD patients (Table 1). We used Inter-Quartile
Range (IQR) criteria to identify outliers and removed 33
patients with longer than 109 days between T1 and T2
from subsequent analyses. As the result, the final analytic
sample contains 627 patients. Due to different pat-
terns of HRQOL change observed over time, patients
treated with SCT and in MED/RAD oncology were
analyzed separately.
The score change was calculated as the difference in
QLQ-C30 between T2 and T1. Nonparametric Spearman
rank correlation coefficients were calculated between QLQ-
C30 score change and response categories of the SSQ. Acal/radiation (MED/RAD) oncology and transplant (SCT)
Clinical service
( n = 191) MED/RAD (n = 436)
% N %
58.1 229 52.5




















displayed on a graphical summary and provided to the clinical team before
tudy design can be found in Berry et al. [16].
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(Table 2, Figures 1 and 2). For reporting purposes, we refer
to entries in the matrix as “instances.” A total of 35 in-
stances were formed across the five QLQ-C30 domains and
seven SSQ rating categories; improvement or deterioration
was represented by 15 instances and “the same” in-
volved 5 instances. For each instance, we calculated the
mean QLQ-C30 score change and the effect sizes (the
mean change score divided the standard deviation).
Negative (or positive) values indicated a lower (or higher)
QLQ-C30 score at T2, and were considered in the same
direction as SSQ rating when deterioration (or improve-
ment) was perceived.
The SSQ rating categories were scored from −3 (very
much worse) to 3 (very much better) with 0 indicating
“about the same.” As suggested by Osoba et al [5], a linear
trend between QLQ-C30 change score and the SSQ rating
was indication that the magnitude of QLQ-C30 score
reflected the degree of change experienced by groups of
patients. In this study we defined the MCID as the mean
difference in QLQ-C30 score changes that reflected one
category change measured by SSQ rating using linear
regression. A two-piece linear model was used allowing
for different slopes of improvement and deterioration
in HRQOL, but was constrained by using the same
intercept. Therefore, by definition, the slopes represent
MCIDs and the intercept was the mean QLQ-C30 score




Table 1 displays demographic and clinical characteristics
for the SCT and MED/RAD groups. As illustrated in
Table 1, most study participants in both patients groups
were white, married/partnered and had some college
education.
QLQ-C30 scores and SSQ ratings
The mean QLQ-C30 scores were significantly lower at
T2 than T1 for PF, SF, CF and the global QOL domains
for both MED/RAD and SCT patients, while higher at
T2 for EF among both patient groups. Table 2 lists the
mean change (95% CI) in QLQ-C30 scores for eachTable 2 Mean change (95% confidence interval) and scale int
Clinical service
Physical function Emotional function
SCT Change −15.80 (−18.44,-13.17) 1.86 (−0.40, 4.13)
Scale* Medium Trivial
MED/RAD Change −4.10 (−5.54, -2.67) 3.15 (1.56, 4.74)
Scale* Trivial Trivial
*Scale interpretation is based on guideline recommended by Cocks et al [13].domain and global QOL. Based on the guidelines on lon-
gitudinal QOL change recommended by Cocks et al. [13],
the decrease is considered medium in PF (−15.8), SF
(−11.76), and CF (−9.51), large in global QOL (−19.19)
among SCT patients; and is considered trivial in PF (−4.10),
SF(−2.91), CF (−1.46) and global QOL (−3.40) among
MED/RAD patients. On the other hand, the mean EF score
increases observed in this study were considered trivial
for SCT patients (1.86) and MED/RAD patients (3.15).
From the SSQ ratings of most subscales (Figure 1),
more patients reported “about the same” than other re-
sponse. More SCT patients perceived deteriorated HRQOL
than improvement while on treatment; for example, 52%
verse 16% on global QOL. MED/RAD patients perceived
rates of improvement similar to those of deterioration; for
example, 25% versus 26% on global QOL.
Association of QLQ-C30 score changes and SSQ ratings
Overall, the correlations between the QLQ-C30 score
change and the SSQ rating categories ranged from 0.28
(SF) to 0.40 (global QOL) among MED/RAD patients,
and from 0.25 (SF) to 0.40 (CF) among SCT patients.
For patients who responded “about the same” on the
SSQ, the mean change in QLQ-C30 for the global QOL
domain deteriorated 14.2 and 2.0 units for SCT and
MED/RAD patients, respectively (Figure 2). The direc-
tion in the mean QLQ-C30 change scores were aligned
with the perceived change reported on the SSQ among
MED/RAD patients; the mean QLQ-C30 score changes
increased, from negative to positive, as corresponding
SSQ ratings indicating better perceived change. This pat-
tern was only observed among SCT patients reporting
deteriorated HRQOL. Among SCT patients with improve-
ment on the SSQ, the mean QLQ-C30 change scores
were negative in most instances, indicating a deteriorat-
ing QLQ-C30 score at T2.
Effect sizes of 0.2, 0.5 and > 0.8 reflect small, moderate,
and large changes, respectively, according to Cohen [19].
Effect sizes for the “about the same” SSQ response were
larger than 0.2 in the global QOL (−0.77), PF (−0.40)
and EF (0.26) among SCT patients, and for EF (0.31)
among MED/RAD patients (Table 3). Effect sizes were
moderate to large (≥ 0.5) in 14/15 (SCT) and 12/15
(MED/RADF) instances when deterioration perceived onerpretation for QLQ-C30 scores after treatment start
QLQ-C30 domain
Social function Cognitive function Global QOL
−11.76 (−16.26, -7.26) −9.51 (−12.62, -6.40) −19.19 (−22.26, -16.12)
Medium Medium Large
−2.91 (−5.27, -0.55) −1.46 (−3.11,-0.20) −3.40 (−5.11, -1.69)
Trivial Small Trivial
Figure 1 Percentage of patients reporting SSQ rating of changes, for SCT (top) and MED/RAD oncology (bottom). Column represents %
of patients.
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ment, only small effect sizes (0.2 to 0.5) in the same direc-
tion as the SSQ ratings were observed in 6/15 (SCT) and
8/15(MED/RAD) instances.
For patients who perceived “about the same” in SSQ,
we identified a significant change in QLQ-C30 scores forFigure 2 The relationship between mean change in QLQ-C30 score an
(bottom), column represent mean change and 95% CI.PF (−9.2), EF (4.1) and global QOL (−15.2) among SCT
patients, and only for EF (4.0) among MED/RAD patients
(Table 4). A linear trend between QLQ-C30 score changes
and the corresponding SSQ ratings was observed when
perceived deterioration in HRQOL was reported; thus,
the defined MCID ranged from 5.7 to 11.4 among SCTd SSQ rating of change for SCT (top) and MED/RAD oncology




















SCT −2.1 −0.97 −1.2 −0.4 −1.17 −0.17 0.04
(12.2) (20.2) (15.0) (13.0) (17.5) (23.9) (22.5)
MED/RAD −1.38 −0.94 −0.42 −0.17 −0.07 −0.02 0.17
(16.5) (18.6) (15.5) (9.5) (16.4) (19.5) (17.9)
Emotional
function
SCT NA −0.76 −0.03 0.26 0.27 0.63 0.47
(13.9) (13.9) (15.5) (13.7) (23.0) (20.1)
MED/RAD −0.86 −0.73 −0.25 0.31 0.44 0.38 0.65
(23.2) (22.9) (16.4) (13.0) (15.1) (21.6) (20.4)
Social
function
SCT −0.69 −0.63 −0.78 −0.08 −0.31 −0.21 0.3
(31.5) (32.2) (25.6) (30.2) (27.1) (39.7) (56.1)
MED/RAD −0.72 −1.18 −0.4 0.02 −0.08 0.16 0.42
(33.4) (22.6) (24.7) (21.3) (29.0) (22.2) (33.8)
Cognitive
function
SCT −1.61 −0.79 −1.02 −0.06 0.51 −0.73 −0.29
(28.5) (23.9) (16.0) (20.4) (19.6) (13.1) (19.2)
MED/RAD −0.48 −0.78 −0.51 0.06 0.43 0.13 0.73
(43.9) (32.6) (18.3) (12.5) (21.6) (16.5) (19.5)
Global QOL SCT −1.28 −1.43 −1.28 −0.77 −0.8 0.26 0.17
(28.2) (20.8) (17.7) (18.4) (17.0) (27.0) (25.0)
MED/RAD −0.77 −1.31 −0.76 −0.13 0.22 0.54 0.17
(43.3) (20.9) (15.9) (15.4) (16.0) (16.3) (20.5)
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(Table 4). For example, in the PF domain, one category
improvement on perceived change in the SSQ rating (e.g.,
from very much worse to moderately worse), was associ-
ated, on average, with a 5.7 unit increase in the QLQ-C30
score change among SCT patients and 7.2 unit increase
among the MED/RAD patients. For the global QOL do-
main, the increase in the QLQ-C30 score changes associ-
ated with one category improvement in the SSQ rating
were 7.3 (SCT) and 11.8 (MED/RAD) units. The MCID






Physical function SCT −9.21 0
MED/RAD −1.30 0.19
Emotional function SCT 4.09 0.0074
MED/RAD 4.04 0
Social function SCT −5.75 0.073
MED/RAD −0.35 0.82
Cognitive function SCT −1.33 0.51
MED/RAD 0.89 0.35
Global QOL SCT −15.22 0
MED/RAD −1.37 0.20was small (2.7 to 3.3). Excepting for the global QOL do-
main (estimate = 6.9), no linear relationship between the
QLQ-C30 change score and the SSQ ratings was observed
for perceived improvement among SCT patients; there-
fore, no meaningful difference was detected.
Discussion
In a large sample of patients with various cancer types
treated at two comprehensive cancer centers, our results
reveal several important observations. First, the SSQ was
a feasible metric with which to conduct an anchor-basede scores and the SSQ rating categories during cancer
Slope-improvement Slope-deterioration
Est. p-value Est. p-value
1.72 0.36 5.70 <.0001
1.11 0.14 7.15 <.0001
2.22 0.17 6.35 .0005
2.68 0.002 9.12 <.0001
3.39 0.41 7.71 .002
2.95 0.042 10.60 <.0001
−0.61 0.82 11.39 <.0001
3.21 0.005 10.79 <.0001
6.85 0.005 7.27 <.0001
3.33 0.0007 11.76 <.0001
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self-reported HRQOL change. Second, modest correla-
tions were found between QLQ-C30 and SSQ, with most
domain scores reflected worse QOL during active ther-
apy as compared to pre-treatment. Third, and perhaps
most notable, was the large discrepancy of the scoring
of diminished physical function and global QOL on the
QLQ-C30 among SCT patients who concurrently per-
ceived no change or improvement in the corresponding
SSQ items. However, about 50% patients reported “about
the same” on the SSQ for most domains, indicating a
perceived stability of HRQOL throughout treatment.
Finally, we found differential MCID estimates among
different domains as well as for improved HRQOL versus
deteriorated HRQOL.
Our findings suggest cancer treatment has a negative
impact on HRQOL among patients with cancer, and that
impact is greater among transplant patients. Based on
recent guidelines [13], the deterioration is regarded as
medium to large among transplant patients for most
domains. These findings support the universal under-
standing that cancer therapy results in multiple side
effects and interferes with nearly all aspects of life. We
observed that PF, SF and CF as well as global QOL deteri-
orated, while EF improved over time. This pattern has
been documented in other longitudinal studies using the
QLQ-C30 ; domain scores related to physical function
diminished from pre-treatment to on- or immediately
after treatment and emotional function improved [20].
The initial anxiety of the diagnosis and treatment initi-
ation period may have been ameliorated by subsequent
familiarity and supportive psychosocial care provided by
the clinical service teams. The greater magnitude of
HRQOL deterioration among SCT patients at T2 (immedi-
ately after hospitalization) is supported by Grulke et al.’s
findings that HRQOL is lowest while in the hospital, but
returns to pre-transplant level one year after transplant [7].
In line with Cohen’s operational definition [19], both
Osoba et al [5] and Cocks et al [8] have recommended
thresholds of trivial (<0.2), small (0.2-0.5) and large (>0.5)
effect sizes. However, we observed a larger magnitude of ef-
fect sizes when “worse” was perceived on the SSQ ratings.
For example, most effect sizes were larger than 0.5 even
when “a little worse” was reported. This is not surprising,
as King previously reported that change in HRQOL ob-
served before and during cancer treatment is often larger
than those observed between two treatment arms [6]. We
also observed large standard deviations for the majority of
instances, indicating diversity in patients’ health conditions
and perceived changes during treatment. On the other
hand, the effect sizes did not vary substantially between the
rating of “a little” and “a lot” among the instances. Given
these phenomena, the interpretation of difference in a given
study requires more consideration and research.The MCID from our study ranged 5.7-11.4 (SCT) and
7.2-11.8 (MED/RAD) among patients reporting deterio-
rated HRQOL; and 2.7-3.4 among MED/RAD patients
reporting improvement, which are in similar magnitude
as previously reported among European patients, with
6–12 points for breast cancer patients [5], and 5–14
points for brain cancer patients [11]. Compared with the
recent guidelines by Cocks et al [13] the range of MCID
is in line with the thresholds for “small” changes which
were referred as “subtle but nevertheless clinical relevant
changes”. Thus, the findings are in agreement from the
two studies. Consistent with previous findings [5,6,8,11,13],
we observed the MCID of QLQ-C30 varied across domains
and among different patient populations. King and col-
leagues [6] also reported different magnitudes in MCID
among different patient groups, supporting differences in
MCID between MED/RAD and SCT patients in our study.
Our results suggest a larger MCID was related to deteri-
oration versus improvement among both MED/RAD and
SCT patients. This phenomenon was previously observed
in other QOL instrument (FACT) [10], as well as in the
QLQ-C30 [12]. In a recent meta-analysis on 118 longitu-
dinal studies, Cocks et al. observed smaller estimates for
improvement than for deterioration [13]. Considering
these available findings, it appears that patients may be
more sensitive to favorable differences, thus, a smaller
MCID should be used to interpret QOL improvement.
We also observed decreases in QLQ-C30 scores among
patients reporting “about the same” in the SSQ for the PF
and global QOL domains. This finding suggests a potential
response shift in scoring of HRQOL. Response shift is
known as the change in internal standards, values, and
the conceptualization of HRQOL after the start of can-
cer treatment [21]. Patients may report a better health
condition even though their actual physical condition
has deteriorated when they perceive a greater survival
benefit from cancer treatment [21,22]. Further exploration
and conceptual work are necessary to better understand
the effect of response shift on patient-reported HRQOL
scores.
The generalizability of our findings to other samples
may be limited; our sample was relatively homogenous
in terms of race and education and was limited to patients
treated at a comprehensive cancer center, and the time
interval under study was specific to before and during can-
cer treatment. Only one anchor (SSQ) was included in the
study and its stability has some discussion [23], thus the
robustness of the identified MCID was checked by com-
paring with previous reports in the literature.
Conclusions
We conducted a systematic and comprehensive evalu-
ation of change in HRQOL before and during treatment
in a large sample of American patients with cancer. Our
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cancer patients’ HRQOL during active therapy. Our
study suggests different MCID thresholds should be ap-
plied to interpret QLQ-C30 change from pre-treatment
to during/post treatment among domains and between
improved and deteriorated HRQOL. Specifically, clinical
attention can be focused on patients who report at least
a 6 point decrease, and for patients who report at least a
3 point increase on QLQ C-30 domains.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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